Takeda receives FDA approval for VELCADE sNDA to treat MM

NewsGuard 100/100 Score

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE®(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

The approval was based on results from a randomized, phase 3, open-label, international, non-inferiority trial conducted in 222 bortezomib-naïve patients with relapsed multiple myeloma (MM). The primary (non-inferiority) objective of the trial was to demonstrate that single agent subcutaneous VELCADE retained at least 60 percent of the overall response rate (ORR) after 4 cycles relative to single agent intravenous VELCADE. Patients in both arms who did not obtain an optimal response (less than complete response (CR)) to therapy with VELCADE alone after 4 cycles were allowed to receive 20 mg of oral dexamethasone daily on the day of and after VELCADE administration. The secondary endpoints of the study included safety and tolerability, ORR and CR rate after 8 cycles, time to progression (TTP), progression free survival (PFS), and one-year overall survival (OS) of the two routes of administration.

Subcutaneous Administration

The pivotal study, published in the Lancet Oncology in May 2011, met its primary efficacy endpoint. Patients receiving VELCADE subcutaneously achieved a 4-cycle ORR of 43 percent and CR rate of 7 percent, while patients receiving VELCADE intravenously achieved an ORR of 42 percent and a CR rate of 8 percent. The overall safety profile was similar between the two arms. However, differences were observed in the incidence of peripheral neuropathy (PN). In the subcutaneous arm of the trial, 6 percent of patients experienced PN of grade 3 or higher, compared with 16 percent in the intravenous arm. In the subcutaneous arm, 38 percent of patients experienced PN of all grades, compared with 53 percent of patients in the intravenous arm.

"Subcutaneous VELCADE is yet another advance in the management of patients with multiple myeloma or relapsed mantle cell lymphoma," said Karen Ferrante, M.D., Chief Medical Officer, Millennium. "The consistency in efficacy findings, and observed differences in peripheral neuropathy, allow physicians to tailor VELCADE treatment for their patients."

"Considering this new subcutaneous route of administration for VELCADE is important for our patients, including those with poor vein access and those with pre-existing peripheral neuropathy or a high risk of developing peripheral neuropathy," said Noopur Raje, M.D. director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center. "It's important to have a range of treatment options to provide the best possible care to each individual patient."

Additional study results at 8 cycles of treatment for subcutaneous and intravenous VELCADE, respectively, included:

  • ORR 53 percent and 51 percent
  • CR rate 11 percent and 12 percent

Additional study results at 11.8-month median follow-up for subcutaneous and intravenous VELCADE, respectively, included:

  • TTP 10.4 months and 9.4 months
  • PFS 10.2 months and 8.0 months
  • OS at 1 year 72.6 percent and 76.7 percent

Grade 3 and above adverse events with differences greater than 5 percent between routes of administration were:

  • Peripheral neuropathy, subcutaneous 6 percent, intravenous 16 percent
  • Thrombocytopenia, subcutaneous 13 percent, intravenous 19 percent
  • Neuralgia, subcutaneous 3 percent, intravenous 9 percent

New Contraindication for Intrathecal Administration

The updated label also includes a contraindication for intrathecal administration as fatal events have occurred with the inadvertent intrathecal administration of VELCADE. VELCADE is for intravenous or subcutaneous use only.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cardiovascular health is intricately linked to the food security status of minoritized groups